Products from SYNkinase

SYNkinase

SYNkinase, headquartered in Australia, is a primary producer of research-use-only biomedical reagents, which it markets to life-science and drug-discovery researchers affiliated with Universities, Research Institutes and Industry. SYNkinase was established in 2008 by Professor Andrew Wilks and Dr Xian Bu. The founders of the company have been involved in pharmaceutical drug discovery for three decades and have extensive scientific, company and board experience.

More information at: synkinase.com

19 from 19 pages
No results were found for the filter!
URMC-099
URMC-099

Item number: SYN-1211-M001

Solid. Soluble in DMSO or water. Inhibition of mixed lineage kinase 3 (MLK-3) is a potential strategy for the treatment of Parkinson's disease and HIV-1 associated neuro-cognitive disorders (HAND), requiring an inhibitor that can achieve significant brain concentration levels. URMC-099 is an orally bioavailable...
Keywords: 3-(1H-Indol-5-yl)-5-(4-(4-methylpiperazin-1-yl)methyl)phenyl)-1H-pyrrolo[2,3- b]pyridine
Application: MLK-3 inhibitor
CAS 1229582-33-5
MW: 421,5 D
From 132.00€ *
Review
BGG463
BGG463

Item number: SYN-1226-M001

CAS 890129-26-7
From 250.00€ *
Review
(+)-JQ1
(+)-JQ1

Item number: SYN-3004-M001

Soluble in DMSO or ethanol. (+)-JQ1 is a potent, high affinity, selective BET bromodomain inhibitor (IC(50) values of 17.7, 32.6, 76.9 and 12942nM respectively for BRD2 (N-terminal (N)), BRD4 (C-terminal (C)), BRD4 (N) and CREBBP, respectively. Target: BET bromodomain
Application: BET bromodomain inhibitor
CAS 1268524-70-4
MW: 457 D
From 165.00€ *
Review
19 from 19 pages